{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:20:40Z","timestamp":1762507240539,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T00:00:00Z","timestamp":1498176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jdcr.2017.06.027","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T03:35:31Z","timestamp":1509939331000},"page":"532-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib"],"prefix":"10.1016","volume":"3","author":[{"given":"Camille","family":"Pinard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Mignard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Samain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-B\u00e9n\u00e9dicte","family":"Duval-Modeste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2017.06.027_bib1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdcr.2017.06.027_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":"Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities","volume":"167","author":"Sinha","year":"2012","journal-title":"Br J Dermatol"},{"issue":"12S1","key":"10.1016\/j.jdcr.2017.06.027_bib3","first-page":"397","article-title":"R\u00e9introduction du vemurafenib apr\u00e8s un rash maculo-papuleux : observation de onze cas","volume":"140","author":"Michaud-Vinez","year":"2013","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jdcr.2017.06.027_bib4","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jamadermatol.2013.5278","article-title":"Vemurafenib induced DRESS","volume":"149","author":"Wenk","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jdcr.2017.06.027_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.annder.2013.10.054","article-title":"Vemurafenib induced toxic epidermal necrolysis","volume":"141","author":"Wantz","year":"2014","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jdcr.2017.06.027_bib6","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/bjd.13522","article-title":"Successfull switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis","volume":"172","author":"Jeudy","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdcr.2017.06.027_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.112.192195","article-title":"Impact of P-Glycoprotein and breast cancer resistance protein on the brain distribution of a novel BRAF inhibitor: vemurafenib","volume":"342","author":"Mittapalli","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jdcr.2017.06.027_bib8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/jpet.112.201475","article-title":"Mechanisms limiting distribution of the Threonine-Protein Kinase B-RafV600E inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases","volume":"344","author":"Mittapalli","year":"2013","journal-title":"J Pharmacol Exp Ther"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251261730139X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251261730139X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:18:25Z","timestamp":1762474705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235251261730139X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S235251261730139X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2017.06.027","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2017.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}